26 May 2013
Keywords: b-m, squibb/merck, co, pargluva, good, phi/ii, drug
Article | 20 June 2005
US drug majors Bristol-Myers Squibb and Merck & Co say that results from a Phase III active-controlled study and a long-term ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 June 2005
24 May 2013
© 2013 thepharmaletter.com